Progress in the diagnosis and management of pulmonary hypertension in children

Current Opinion in Pediatrics

Volumn 26, Issue 5, 2014, Pages 527-535

  Nicolarsen, Jeremy ^a   Ivy, Dunbar ^a  

^a CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Bronchopulmonary dysplasia; Diagnosis; Pediatrics; Pulmonary hypertension; Treatment

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; MACITENTAN; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; RIOCIGUAT; SILDENAFIL; TADALAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT;

ANTICOAGULANT THERAPY; CARDIOPULMONARY EXERCISE TEST; CHILD; CHILDHOOD DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DIURETIC THERAPY; ECHOCARDIOGRAPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG DYSPLASIA; MEDICAL EXPERT; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PEDIATRICS; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; TISSUE DOPPLER IMAGING; VASCULAR BIOLOGY; VASODILATATION; BRONCHOPULMONARY DYSPLASIA; DISEASE COURSE; HEART CATHETERIZATION; HYPERBARIC OXYGEN; HYPERTENSION, PULMONARY; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS;

ANTIHYPERTENSIVE AGENTS; BRONCHOPULMONARY DYSPLASIA; CARDIAC CATHETERIZATION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DIURETICS; HUMANS; HYPERBARIC OXYGENATION; HYPERTENSION, PULMONARY; PREVALENCE; PROGNOSIS;

EID: 84928208035     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000135     Document Type: Review

References (70)

1. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:S5-S12.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54.
3. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34-D41.
4. Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32:1385-1389.
5. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (Caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5:336-343.
6. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369:351-361.
7. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:S13-S24.
8. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol Mech Dis 2007; 2:369-399.
9. Fraisse A, Jaïs X, Schleich J-M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010; 103:66-74.
10. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: A comparison between children and adults. Eur Respir J 2011; 37:665-677.
11. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125:113-122.
12. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: A registry study. Lancet 2012; 379:537-546.
13. Ali Z, Schmidt P, Dodd J, Jeppesen DL. Predictors of bronchopulmonary dysplasia and pulmonary hypertension in newborn children. Dan Med J 2013; 60:A4688-A4698.
14. An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010; 40:131-136.
15. Bhat R, Salas AA, Foster C, et al. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. J Pediatr 2012; 129:e682- e689.
16. Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia. Curr Opin Pediatr 2013; 25:329-337.
17. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. J Pediatr 2007; 120:1260-1269.
18. Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol 2014; 27:8-16.
19. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42-D50.
20. Lafitte S, Pillois X, Reant P, et al. Estimation of pulmonary pressures and diagnosis of pulmonary hypertension by Doppler echocardiography: A retrospective comparison of routine echocardiography and invasive hemodynamics. J Am Soc of Echocardiogr 2013; 26:457-463.
21. Haddad F, Guihaire J, Skhiri M, et al. Septal curvature is a marker of hemodynamic, anatomical, and electromechanical ventricular interdependence in patients with pulmonary arterial hypertension. Echocardiography 2014; 31:699-707.
22. Alkon J, Humpl T, Manlhiot C, et al. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am J Cardiol 2010; 106:430-436.
23. Jone P-N, Hinzman J, Wagner BD, et al. Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension. J Am Soc of Echocardiogr 2014; 27:172-178.
24. Kassem E, Humpl T, Friedberg MK. Prognostic significance of 2-dimensional, M-mode, and Doppler echo indices of right ventricular function in children with pulmonary arterial hypertension. Am Heart J 2013; 165:1024-1031.
25. Lammers AE, Haworth SG, Riley G, et al. Value of tissue Doppler echocardiography in children with pulmonary hypertension. J Am Soc of Echocardiogr 2012; 25:504-510.
26. Takatsuki S, Nakayama T, Jone P-N, et al. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension. J Pediatr 2012; 161:1126-1131.
27. Moledina S, Pandya B, Bartsota M, et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Circ Cardiovasc Imaging 2013; 6:407-414.
28. Truong U, Fonseca B, Dunning J, et al. Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension. J Cardiovasc Magn Reson 2013; 15:81.
29. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986; 89:497- 503.
30. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
31. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111.
32. Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62:D117-D126.
33. Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010; 106:1332-1338.
34. Douwes JM, van-Loon RLE, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 2011; 32:3137-3146.
35. Di-Maria MV, Younoszai A, Mertens L, et al. RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes. Heart 2014; 100:1342-1347.
36. Rausch CM, Taylor AL, Ross H, et al. Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. Int J Cardiol 2013; 169:445-448.
37. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122:164-172.
38. Lammers A, del-Cerro M, Freudenthal A, et al. Functional classification of pulmonary hypertension in children: report from the PVRI pediatric taskforce Panama 2011. Pulm Circ 2011; 1:280-285.
39. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98:525-529.
40. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129:1313-1321.
41. Van-Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63:321-327.
42. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135:745-751.
43. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135:21- 26.
44. West J, Austin E, Fessel JP, et al. Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. Drug Discov Today 2014; doi: 10.1016/j.drudis.2014.04.015.
45. Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 38:70-77.
46. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2012; 48:27-34.
47. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809-818.
48. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012; 33:683-688.
49. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125:324-334.
50. Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naïve pediatric pulmonary arterial hypertension. Circulation 2014; 129:1914-1923.
51. Commissioner OOT. Safety alerts for human medical products - Revatio (sildenafil): drug safety communication - recommendation against use in children. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm. [Accessed 30 August 2012].
52. Commissioner OOT. Safety alerts for human medical products - Revatio (sildenafil): drug safety communication - FDA clarifies warning about pediatric use for pulmonary arterial hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm390876.htm. [Accessed 31 August 2014].
53. Roldan T, Deiros L, Romero JA, et al. Safety and tolerability of targeted therapies for pulmonary hypertension in children. Pediatr Cardiol 2013; 35:490-498.
54. Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013; 187:572-575.
55. Douwes JM, Roofthooft MTR, Van-Loon RLE, et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart 2014; 100:224-230.
56. Zijlstra WM, Douwes JM, Rosenzweig EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014; 63:2159-2169.
57. Limsuwan A, Wanitkul S, Khosithset A, et al. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J of Cardiol 2008; 129:333-338.
58. Krishnan U, Takatsuki S, Ivy DD, et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol 2012; 110:1704-1709.
59. Takatsuki S, Parker DK, Doran AK, et al. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatr Cardiol 2012; 34:1006-1012.
60. Siehr SL, Dunbar Ivy D, Miller-Reed K, et al. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant 2013; 32:546-552.
61. Levy M, Celermajer DS, Bourges-Petit E, et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011; 158:584-588.
62. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol 1998; 32:297-304.
63. Goldstein BS, Sweet SC, Mao J, et al. Lung transplantation in children with idiopathic pulmonary arterial hypertension: An 18-year experience. J Heart Lung Transplant 2011; 30:1148-1152.
64. Baruteau A-E, Serraf A, Lévy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg 2012; 94:817-824.
65. Esch JJ, Shah PB, Cockrill BA, et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant 2013; 32:381-387.
66. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36:792-799.
67. Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369:319-329.
68. CDER F. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC); 2013. 1-315.
69. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension. Circulation 2013; 127:624-633.
70. Tapson VF, Jing ZC, Xu K-F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): A randomized controlled trial. Chest 2013; 144:952-958.